Genome-Scale CRISPR Screens Identify Human Pluripotency-Specific Genes.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
09 04 2019
Historique:
received: 18 05 2018
revised: 20 12 2018
accepted: 13 03 2019
entrez: 11 4 2019
pubmed: 11 4 2019
medline: 23 6 2020
Statut: ppublish

Résumé

Human pluripotent stem cells (hPSCs) generate a variety of disease-relevant cells that can be used to improve the translation of preclinical research. Despite the potential of hPSCs, their use for genetic screening has been limited by technical challenges. We developed a scalable and renewable Cas9 and sgRNA-hPSC library in which loss-of-function mutations can be induced at will. Our inducible mutant hPSC library can be used for multiple genome-wide CRISPR screens in a variety of hPSC-induced cell types. As proof of concept, we performed three screens for regulators of properties fundamental to hPSCs: their ability to self-renew and/or survive (fitness), their inability to survive as single-cell clones, and their capacity to differentiate. We identified the majority of known genes and pathways involved in these processes, as well as a plethora of genes with unidentified roles. This resource will increase the understanding of human development and genetics. This approach will be a powerful tool to identify disease-modifying genes and pathways.

Identifiants

pubmed: 30970262
pii: S2211-1247(19)30359-6
doi: 10.1016/j.celrep.2019.03.043
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

616-630.e6

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Robert J Ihry (RJ)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA. Electronic address: robert.ihry@novartis.com.

Max R Salick (MR)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Insitro, South San Francisco, CA 94080, USA.

Daniel J Ho (DJ)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

Marie Sondey (M)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Abbvie, Cambridge, MA 02139, USA.

Sravya Kommineni (S)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Casma Therapeutics, Cambridge, MA 02139, USA.

Steven Paula (S)

Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

Joe Raymond (J)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

Beata Henry (B)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

Elizabeth Frias (E)

Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

Qiong Wang (Q)

Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

Kathleen A Worringer (KA)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

Chaoyang Ye (C)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Blueprint Medicines, Cambridge, MA 02139, USA.

Carsten Russ (C)

Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

John S Reece-Hoyes (JS)

Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

Robert C Altshuler (RC)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

Ranjit Randhawa (R)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Axcella Health, Cambridge, MA 02139, USA.

Zinger Yang (Z)

Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; University of Massachusetts Medical School, Worcester, MA 01655, USA.

Gregory McAllister (G)

Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Sana Biotechnology, Cambridge, MA 02139, USA.

Gregory R Hoffman (GR)

Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Sana Biotechnology, Cambridge, MA 02139, USA.

Ricardo Dolmetsch (R)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

Ajamete Kaykas (A)

Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Insitro, South San Francisco, CA 94080, USA. Electronic address: akaykas@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH